GleamWall
中文EN

CALC CalciMedica, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1534133 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY34.5%
TTM EPS YoY152.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-763.3%
ROA-103.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets70.4%
Debt / equity0.00x
Current ratio4.96x
Interest coverage-14.15x

Cash quality & payout

Operating cash flow / net income1.20x
Accruals ratio21.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$2.32M$2.10M$3.48M$3.11M$3.85M$4.05M$4.22M$3.83M
SG&A expense$2.43M$1.91M$2.13M$1.28M$1.77M$2.57M$2.27M$2.34M
Operating income-$4.75M-$4.01M-$5.61M-$4.38M-$5.62M-$6.62M-$6.50M-$6.17M
Interest expense$357,000$325,000$319,000$325,000$326,000$324,000$447,000$0
Income tax$0$0$0$0$0$0$0$0
Net income-$1.67M-$7.65M$4.98M-$10.76M-$7.80M-$5.96M-$5.04M-$4.26M
EBITDA-$4.74M-$4.00M-$5.60M-$4.38M-$5.61M-$6.61M-$6.48M-$6.16M
EPS (basic)-0.24-0.450.31—-2.59-0.40-0.36—
EPS (diluted)-0.24-0.450.30—-2.59-0.40-0.36—
Weighted avg. shares (diluted)6.91M17.10M16.33M—3.02M15.00M14.12M—
Banking
Noninterest income$134,000$54,000$106,000$151,000$140,000$220,000$202,000$214,000
Balance sheet
Cash & equivalents$4.57M$18.62M$8.16M$11.52M$5.47M$5.92M$12.56M$7.93M
Short-term investments$9.19M$0$0$1.50M$8.61M$12.04M$12.07M$10.73M
Current assets$14.22M$19.46M$8.55M$13.53M$14.85M$18.96M$25.22M$19.66M
PP&E, net$72,000$36,000$43,000$50,000$49,000$105,000$118,000$119,000
Total assets$14.29M$19.50M$8.61M$13.59M$14.91M$19.08M$25.35M$19.79M
Current liabilities$2.87M$3.49M$5.31M$3.78M$3.68M$3.48M$4.46M$3.68M
Total liabilities$10.07M$13.99M$9.71M$20.23M$15.18M$12.98M$14.46M$5.38M
Shareholders' equity$4.23M$5.51M-$1.10M-$6.64M-$268,000$6.10M$10.89M$14.41M
Shares outstanding6.89M30.74M15.75M3.09M14.26M13.97M13.97M13.48M
Cash flow statement
Operating cash flow-$3.86M-$4.62M-$4.86M-$4.85M-$4.78M-$6.67M-$4.88M-$4.97M
Capital expenditure$0$0$0$6,000$8,000$5,000$9,000$2,000
Free cash flow-$3.86M-$4.62M-$4.86M-$4.86M-$4.79M-$6.67M-$4.89M-$4.97M
Investing cash flow-$9.14M$42,000$1.50M$7.15M$3.51M$134,000-$1.24M-$5.17M
Financing cash flow-$1.04M$15.03M$0$3.75M$818,000-$102,000$10.74M$8.92M
Depreciation & amortization$7,000$7,000$7,000$5,000$12,000$14,000$15,000$14,000
Stock-based compensation$496,000$540,000$561,000$622,000$625,000$1.18M$549,000$632,000

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.